miR-100 Reverses Cisplatin Resistance in Breast Cancer by Suppressing HAX-1

Background/Aims: Breast cancer (BC) is the most common cancer in women worldwide. Despite great advancements in cancer therapy in recent years, surgery and chemotherapy are still the mainstays of BC treatment. However, cancer cells usually develop mechanisms to evade cell death induced by chemothera...

Full description

Bibliographic Details
Published in:Cellular Physiology and Biochemistry
Main Authors: Guojun Wu, Wenhong Zhou, Xiaohua Pan, Yongjie Sun, Hao Xu, Peng Shi, Jiyu Li, Ling Gao, Xingsong Tian
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2018-07-01
Subjects:
miR-100
HAX-1
Cisplatin
Resistance
Breast cancer
Online Access:https://www.karger.com/Article/FullText/491476

Internet

https://www.karger.com/Article/FullText/491476

Similar Items